Breaking News
Get 55% Off 0
Get Premium Data for Cyber Monday: Up to 55% Off InvestingPro
CLAIM SALE
Close

Clinuvel Pharmaceuticals Ltd ADR (CLVLY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.340 -0.120    -1.42%
07/12 - Closed. Currency in USD
  • Volume: 278
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 8.340 - 8.340
Type:  Equity
Market:  United States
Clinuvel Pharmaceuticals ADR 8.340 -0.120 -1.42%

CLVLY Financial Summary

 
A brief financial summary of Clinuvel Pharmaceuticals Ltd ADR as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Clinuvel Pharmaceuticals Limited reported earnings results for the full year ended June 30, 2024. For the full year, the company reported revenue was AUD 95.31 million compared to AUD 82.99 million a year ago. Net income was AUD 35.64 million compared to AUD 30.6 million a year ago. Basic earnings per share from continuing operations was AUD 0.715 compared to AUD 0.619 a year ago. Diluted earnings per share from continuing operations was AUD 0.698 compared to AUD 0.591 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

CLVLY Income Statement

Gross margin TTM 91.23%
Operating margin TTM 55.08%
Net Profit margin TTM 40.41%
Return on Investment TTM 19.45%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Jun 30, 2023 Mar 31, 2023
Total Revenue 27.69 27.69 24.48 24.48
Gross Profit 25.04 25.04 22.35 22.35
Operating Income 17.34 17.34 14.93 14.93
Net Income 9.61 9.61

CLVLY Balance Sheet

Quick Ratio MRQ 8.28
Current Ratio MRQ 8.81
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 0.43%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Jun 30, 2023 Mar 31, 2023
Total Assets 193.71 193.71
Total Liabilities 29.08 29.08
Total Equity 164.63 164.63

CLVLY Cash Flow Statement

Cash Flow/Share TTM 0.74
Revenue/Share TTM 1.76
Operating Cash Flow  -
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 7.94 7.94
Cash From Investing Activities -0.316 -0.316
Cash From Financing Activities -0.047 -0.047
Net Change in Cash 8.06 8.06
* In Millions of AUD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CLVLY Comments

Write your thoughts about Clinuvel Pharmaceuticals Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email